Fundz

Treace

Ponte Vedra, Florida, United States · Biotechnology, Healthcare, Health Care

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans1, of which Treace estimates 1.1 million are annual s

Key facts

Headquarters
Ponte Vedra, Florida, United States
Employees
Unknown
Industries
Biotechnology, Healthcare, Health Care
Status
Public (TMCI)
Website
treace.com
LinkedIn
Company page

Recent activity at Treace

  • : SEC 8-K (5.02): Effective as of the close of business on April 8, 2026, Gaetano M. Guglielmino, Chief Commercial Officer of Treace Medical Concepts, Inc., will depart from the Company. His responsibilities will be assumed by existing employees, with the Senior Vice President, Sales reporting directly to CEO John T. Treace. Mr. Guglielmino’s departure is not related to any disputes with the Company. To aid in the transition, he has entered into a Consulting Services Agreement effective April 9, 2026, which includes a monthly fee of $36,666.67, COBRA premium payments, a pro-rated annual target bonus, and continued vesting of equity awards until January 31, 2027. The Company does not plan to fill the Chief Commercial Officer role, highlighting a strategic shift in management structure.
  • : SEC 8-K (7.01): On January 13, 2026, Treace Medical Concepts, Inc. posted an investor presentation which is accessible through its investor relations website. This presentation is intended for use in upcoming meetings with analysts and investors, notably at the J.P. Morgan Healthcare Conference scheduled for January 14, 2026, at 7:30 am Pacific Time. The filing includes details about the presentation, which is furnished as Exhibit 99.2, but the information is not deemed 'filed' under Section 18 of the Exchange Act and carries no liability under that section. The company aims to enhance investor engagement and transparency through this presentation, signifying potential strategic initiatives and updates for stakeholders.
  • : SEC 8-K (1.01): On December 17, 2025, Treace Medical Concepts, Inc. entered into a Loan and Security Agreement with SLR Investment Corp., providing a 60-month term loan facility of up to $125 million, with an initial draw of $60 million. Additionally, a Revolving Loan Agreement with Gemino Healthcare Finance offers a revolving facility of $30 million, potentially expandable to $50 million. The interest rates for the loans are based on the SOFR index, with terms including interest-only payments for the first 48 months. Importantly, $55 million of the term loan is contingent on achieving specified revenue objectives. This strategic financing positions the Company to support its operational growth and manage its financial commitments effectively.
  • : SEC 8-K (1.01): On December 17, 2025, Treace Medical Concepts, Inc. entered into two significant Loan Agreements: a Term Loan Agreement with SLR Investment Corp. allowing up to $125 million in borrowing capacity, drawing $60 million upon closing, and a Revolving Loan Agreement with Gemino Healthcare Finance, LLC providing an additional $30 million. The Term Loan includes revenue-based contingencies for further borrowing of up to $65 million. These agreements are crucial for supporting the company's operational and strategic growth initiatives.
  • : SEC 8-K (5.02): On November 3, 2025, Richard W. Mott retired from his position as a member of the Board of Directors of Treace Medical Concepts, Inc. His retirement included his roles on the Compensation Committee, Nominating and Corporate Governance Committee, and as Lead Independent Director. The retirement was due to personal reasons and not from any disagreement with the company. Following Mr. Mott's retirement, on November 5, 2025, the Board reduced its size from eight to seven members, resulting in no vacancies on the Board.
  • : Treace Medical Concepts, Inc. Launches IntelliGuide™ PSI for Personalized Surgical Treatment of Midfoot Deformities.
  • : Guy Guglielmino Joins Treace Medical Concepts, Inc. as Chief Commercial Officer
  • : Treace Medical Completes Acquisition Of Technology Enabling Patient Specific Instrumentation And Reports On Clinical Cases Using Psi With The Lapiplasty® System
  • : Treace Medical Concepts To Acquire Technology Enabling Patient Specific Instrumentation For Foot And Ankle Surgeries
  • : Treace Secures Up To $150 Million In Debt Financing

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Treace funding history

DateRoundAmount
May 2022Debt Financing$150.0M
May 2017Venture$5.9M
Feb 2017Venture$2.1M

Leadership

  • RICHARD MOTT, Director
  • JOHN TREACE, Director
  • F BAYS, Director
  • JAMES TREACE, Director
  • THOMAS TIMBIE, Director

Verified email and direct lines for Treace’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Treace files 5 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Treace in the news

Companies similar to Treace

  • RIVANNA · Biotechnology, Healthcare, Health Care, Manufacturing, Medical, Medical Device
  • SynerFuse, Inc. · Biotechnology, Healthcare, Health Care, Manufacturing, Medical, Medical Device
  • Monteris Medical · Biotechnology, Healthcare, Health Care, Manufacturing, Medical, Medical Device
  • Dror Ortho-Design · Biotechnology, Healthcare, Health Care, Manufacturing, Medical, Medical Device
  • Tenon Medical · Biotechnology, Healthcare, Health Care, Manufacturing, Medical, Medical Device

About Treace: questions and answers

What does Treace do?

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans1, of which Treace estimates 1.1 million are annual s

Where is Treace headquartered?

Treace is headquartered in Ponte Vedra, Florida, United States.

Has Treace raised funding?

Yes. Fundz has recorded 3 funding events for Treace. The most recent, Debt Financing of $150.0M, was in May 2022.

What is the latest news on Treace?

On Nov 6, 2025, SEC 8-K (5.02): Effective as of the close of business on April 8, 2026, Gaetano M. Guglielmino, Chief Commercial Officer of Treace Medical Concepts, Inc., will depart from the Company. His responsibilities will be assumed by existing employees, with the Senior Vice President, Sales reporting directl

Is Treace a public company?

Yes. Treace is publicly traded under the ticker TMCI.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Treace across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.